Moderna Is Losing Billions. Here's Why That Might Be Exactly the Right Strategy.

Lynch syndrome is an inherited condition affecting 1 in 300 people that causes lifetime cancer risk of up to 80%[1]The ...

Moderna secures up to $50 million to develop an Ebola vaccine.

Shares of Moderna (NASDAQ:MRNA) are up roughly 6% in Monday morning trading, changing hands near $57.52 after Friday’s close of $54.35. The intraday move extends what has already been a powerful 2026 ...

Oxford and Moderna’s preventive mRNA cancer vaccine enters trials, targeting high-risk Lynch syndrome patients to train ...

CAMBRIDGE, MA / ACCESS Newswire / July 30, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Commission (EC) has granted marketing authorization for the updated formulation of the ...

When used alongside Merck’s Keytruda, Moderna’s personalized cancer vaccine halved the risk of death or disease recurrence in ...

Moderna’s mRNA flu vaccine gave more protection against illness than the standard flu shot in a phase 3 clinical trial, according to published results.

Global health foundation Coalition for Epidemic Preparedness Innovations (CEPI) will invest $50 million to support ...

A top adviser has resigned from the Food and Drug Administration's (FDA) vaccine advisory committee amid concerns about her ...

CEPI is committing up to $50 million to support Moderna's vaccine candidate for the strain with no approved shot ...

Global pharmaceutical companies Moderna and MSD announced on the 1st, local time, the results of a joint Phase 2 clinical ...